NBPF member 14Genealiases: AE5 · DJ328E19.C1.1 · NBPF
Q-omics provides the consensus-scored NBPF14 profile across patient tissues and cancer cell-line models. NBPF14 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NBPF14 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NBPF14 RNA expression shows 19,769 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where NBPF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF14 survival associations across molecular data types. NBPF14 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF14 RNA expression–survival associations across cancer types. High NBPF14 expression shows unfavorable associations in ACC, OV, MESO, KIRP, CHOL and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NBPF14 RNA expression.
This table summarizes NBPF14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF14 shows lower tumor expression in COAD, UCEC and KICH and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher NBPF14 RNA expression in tumor versus normal tissue (log2 FC = +0.335, t-test p < 0.001).
This table shows molecular features associated with NBPF14 in patient tissues and cancer cell lines. In patient samples, NBPF14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
